INVEST WITH VIVASPARKLE

Join our Human Longevity and Rejuvenation Syndicate

Ken Scott 048 (1)

WHO DO WE INVEST IN ?

To most people longevity implies living until perhaps the 80s or 90s or even to 100+, but tied with a continual degradation of the physical and mental self. Longevity, as we view it, implies extending life at least that far but perhaps even much further. Tied to that increased lifespan is a need to rejuvenate the body to stabilize it at or rejuvenate it to a younger physical age. 

Indeed some proof of concept scientific work of the past few years offers the prospect of immortality. “We will explain and explore these concepts on our rejuvenated VivaSparkle!” Through our Human Longevity and Rejuvenation syndicate we offer you the opportunity to join us in promoting longevity through investments in some of the leading companies who are developing these rejuvenating technologies”

 

During the past several years as we have been exploring and learning about the longevity space of biotechnology. We continually come across start up firms that are leading the way to providing the longevity and rejuvenation we all seek.

We have invested in a number of these companies and continue to do so. We are now able to offer the opportunity for investors to join us in such investments through our Human Longevity and Rejuvenation Syndicate which provides capital at early stages to promote.

If you wish to join us in these investments please contact us using the contact button below.

Why you should invest with our Human Longevity and Rejuvenation Syndicate?

VivaSparkle’s Human Longevity and Rejuvenation syndicate is managed by Kenneth Scott, an entrepreneur, investor, biotech-enthusiast who invests in startups and identifies breakthrough technologies that enhance longevity.

In addition to that, he wants to give investors the opportunity for significant financial returns using his knowledge and intuitions to identify promising companies.

If you are looking to invest in biotechnology startups that are aiming to improve human lives by introducing breakthrough technologies in the longevity space, but do not have an appropriate scientific background, it is difficult to decide which startups to back. Kenneth Scott manages VivaSparkle’s Human Longevity and Rejuvenation syndicate  which allows investors to join him in investing in the companies that are considered more likely than others to succeed and improve human lives.

 

What will I get from joining the syndicate?

Anyone who joins the syndicate, will have the opportunity to invest in carefully selected longevity related companies. We believe in the potential of the companies to help humanity and to potentially provide significant financial return to investors.

VivaSparkle is offering you the opportunity to join with VivaSparkle in companies that they are investing in.

VivaSparkle provides regular reports on each investment through close interaction with the companies involved

You can invest with VivaSparkle through our Investment Syndicate at AngelList.  Once you join the syndicate, you will be advised of selected opportunities for investment which you can choose whether or not to participate in.

The syndicate will provide selected companies to invest in and to stay up to date on their progress with regular reports.

JOINING THE SYNDICATE

To join our Human Longevity and Rejuvenation syndicate syndicate, you will have to open an account at the AngelList Website which unites startups and investors looking to work together.

AngelList’s Syndicate is a way to facilitate startups financing with accredited investors maintaining a mutual trust with all the regulations and legal matters.

Once your AngelList account is approved click on the button below to join our Human Longevity and Rejuvenation syndicate:

Click on “Back Syndicate”.

After you click on Back Syndicate, a new window pops up and now you can write a one-to-one application to VivaSparkle.

SOME OF Our INVESTMENTS

You would like to know about the Syndicate?

Send us an email by writing your message in the following contact form.

We will respond within the next 24-72 hours.

 

CONTACT FORM

Scroll to Top

Longevity Hackers Film

Longevity Hackers is a documentary in production about interventions that are being used by various people (‘hackers’) to promote their personal longevity. The documentary will have interviews of many of the leading proponents of extending lifetime beyond the currently known maximum life for humans of about 120 years. 

Persons interviewed for the film include such well known leaders in the field as George Church, Nir Barzelai, Bill Andrews, Liz Parrish, Sergey Young . . . . Kenneth Scott has also been interviewed for this film.

Repair Biotechnologies

Repair Biotechnologies develops the Cholesterol Degrading Platform (CDP), allowing cells to safely break down a toxic excess of cholesterol, and thereby reverse the pathology of cholesterol-based conditions such as atherosclerosis.

The first (cardiovascular disease, 16%) and second (stroke, 11%) top causes of human mortality both result from atherosclerosis. The CDP has proven very successful in mice trials and the company is moving forward to human clinical trials in 2022.

Leucadia Therapeutics

Leucadia Therapeutics’ medical device, Arethusta, restores cerebrospinal fluid (CSF) drainage across the cribriform plate to prevent toxic metabolites from accumulating in the brain. It has the potential to reverse early Alzheimer’s disease and help hundreds of millions of people. 

Over the past few years, Leucadia laid the foundation for a clinical trial by rewriting the (anatomical) book on cribriform plate biology, established that CSF egress slows with age, and showed that blocking the cribriform plates of ferrets induced a syndrome similar to early Alzheimer’s disease. 

This work provided conclusive evidence that cribriform plate blockage is an apical mechanism in Alzheimer’s disease.

We will begin clinical trials of Arethusta in California, followed by more sites in the US, Canada, the EU, UK, Japan, and Korea. Regulatory approval of medical devices is significantly faster and an order of magnitude cheaper than drug trials, so our primary endpoints will be ready within three years.

Auctus Biologics

Monoclonal antibodies are a major class of therapeutics with a dozen or more being approved by the FDA every year. These treatments have huge annual revenues, with Humira (treating arthritis) grossing over $20B and Herceptin (treating HER2 breast cancer) grossing over $6B. 

The Auctus ntibody mimetic platform has significant potential to reduce costs, allowing delivery to a much larger group of patients. Auctus is already in negotiation with some of the major pharmceutical companies for sale and/or licencing of its technology.

Are you already investing with Vivaparkle?

If you have already joined our Human Longevity and Rejuvenation Syndicate, please click the button below to log in to your AngelList.co account.